Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protect healthy tissue from the damaging effects of radiation. The company’s first compound, AEOL 10150, is being developed for oncology uses, in combination with radiation therapy. It is also being developed, with funding from the US government as a medical countermeasure against chemical and radiological weapons.
The company today announced the appointment of Russell L. Skibsted as senior vice-president and chief financial officer. Mr. Skibsted is a seasoned executive with over 25 years of experience in finance, acquisitions, partnering, marketing and operations. He has worked with companies of all sizes, ranging from start-ups to Fortune 500 companies.
Prior to joining Aeolus, Mr. Skibsted was senior vice-president and chief business officer of Spectrum Pharmaceuticals where he led global strategy, licensing, fund raising and mergers and acquisitions. Previously, he was CFO at Hana Biosciences where he led the process of bringing the company public.
Before joining Hana, Mr. Skibsted was partner and CFO at Asset Management Company, one of the oldest and most respected Silicon Valley venture capital firms. While there, he oversaw the financial and administrative functions, public and private portfolios, and aviation operations.
The president and CEO of Aeolus Pharmaceuticals, John L. McManus, believes that Mr. Skibsted will make a strong addition to the company’s management team. Mr. McManus stated, “His extensive financial management experience, strategic planning skills, and leadership will be outstanding assets to Aeolus as we enter the next phase of our company’s development and transition to a period of rapid growth.”
For more information about Aeolus Pharmaceuticals, please visit the company’s website at www.aeoluspharma.com